Zynex Inc. Submits FDA 510(k) Application for Innovative NiCO Laser Pulse Oximeter, Marking Key Milestone in Regulatory Review
ENGLEWOOD, Colo., May 12, 2025 - Zynex, Inc. $(ZYXI)$, a leader in medical technology, has submitted a 510(k) application to the U.S. Food and Drug Administration (FDA) for its NiCO™ Noninvasive CO-Oximeter device. This submission is a significant step in the company's efforts to innovate within the field of patient monitoring. The NiCO Laser Pulse Oximeter is designed to provide more reliable and accurate oxygen status information, potentially revolutionizing the pulse oximetry market, which is projected to grow from $2.8 billion today to $4.3 billion by 2027. The device aims to enhance patient care by offering real-time data on various hemoglobin species, enabling earlier detection of conditions such as hypoxia and hyperoxia.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zynex Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001558370-25-007779), on May 14, 2025, and is solely responsible for the information contained therein.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。